METHODS AND MATERIALS
Findings in all the articular synovial fluid (SF) samples received over a 4-year period were reviewed. Altogether, 1945 samples were examined of which 27% were from RA patients, 22% from other inflammatory arthropathies (including crystal arthropathies) and 34% from osteoarthritis patients. In most other cases the diagnosis was either unknown or not recorded. The RA samples came predominantly from the knee (66%) and shoulder (22%) joints but other sites such as the elbow (4%) and the wrist (1%) were also represented. Multiple samples from both the knee and shoulder joints were available in many RA patients. Bursal and tendon sheath aspirates were not included in the study.
Cholesterol crystals were considered present if polarized light microscopy showed the typical flat pleomorphic plates often with a chip out of one corner [6] (Fig. 1) . In all cases the crystals were also soluble in ethanol, indicating lipid. Other possible forms of cholesterol such as needle-shaped crystals [4, 5] and other lipids were not considered.
RESULTS
There were 14 samples (from six patients) in which the typical crystals were identified. Details of the patients and the SF are shown in the Table. All the patients had severe erosive nodular RA in a typical polyarticular distribution. Rheumatoid factor was positive in high titre in all but one case (patient no.4).
The shoulder was the joint from which the crystals were isolated in all cases. None occurred in the knee or other locations.
Clinically, the involved shoulder was the most symptomatic joint in four patients. It was both painful and severely restricted in all cases with a large anterior effusion present in most (Fig. 2) . The shoulder radiographs showed severe erosive changes in all cases (Fig. 3) . In the four patients from whom multiple samples were available crystals were detected in the same joint at each showing severe erosive changes. [7] suggested impaired lymphatic drainage of the joint. Zuckner et al. [3] suggested that deficient removal of red blood cells after local intra-articular haemorrhage is important although blood staining has not been a feature of fluids containing the crystals in this series or other reported cases. As cell membranes are thought to provide a source of cholesterol in such effusions, these, or other, local factors could act by causing an accumulation of cell debris thus providing a suitable substrate for the formation of cholesterol crystals. Clearly other factors must also play a part in their formation in SF.
The finding of cholesterol crystals in chronic bursae and calf cysts [3, 5] also implicates local factors such as reduced drainage, and it was striking that all our patients had persistent large effusions in the affected shoulders.
There is some evidence in experimental animals that the crystals may cause a low-grade inflammation [3, 7, 8] . Zuckner and colleagues suggested that this may be self-perpetuating by inducing 'chronicity of the pathological state'. There are however few data to support this in man and further work is required. In our patients there was nothing to suggest that the crystals played any role in the pathogenesis of the joint disease.
It is well recognized that crystals such as monosodium urate and calcium pyrophosphate dihydrate favour certain joints as sites for their formation. Our data suggest that the shoulder joint is the particular site favoured for the formation of cholesterol crystals in RA patients. It is likely therefore that their detection in the shoulder joint merely reflects this predilection in chronic severe RA and probably carries no other clinical or pathological significance.
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